Clinical usefulness of probiotics in inflammatory bowel diseases

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 9, 2006, Pages 23-33

  Mach, Tomasz ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Department of Gastroenterology Hepatology and Infectious Diseases ^*  (Poland)

Author keywords

Crohn's disease; Inflammatory bowel disease; Pouchitis; Probiotics; Ulcerative colitis

Indexed keywords

5 ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; BALSALAZIDE; CIPROFLOXACIN; CORTICOSTEROID; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ANASTOMOSIS; BIFIDOBACTERIUM; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; ENDOSCOPY; ENTERITIS; ENTEROCOCCUS; ESCHERICHIA COLI; GROWTH INHIBITION; HOMEOSTASIS AND REGULATION; HUMAN; ILEITIS; IMMUNOREGULATION; INTESTINE FLORA; INTESTINE RESECTION; LACTOBACILLUS; LOW DRUG DOSE; MONOTHERAPY; PATHOGENESIS; PROCTOCOLECTOMY; PROPHYLAXIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; POUCHITIS; PROBIOTICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34147095993     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Feagan BG, McDonald JWD. Crohn's disease. In Evidence-based gastroenterology and Hepatology, JWD McDonald, AK Burroughs, BG Feagan (eds). London, BMJ Blackwell Publishing, 2004, pp. 179-195.
2. Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J 2006; 82: 376-382.
3. Chermesh I, Eliakim R. Probiotics and the gastrointestinal tract: Where are we in 2005? World J Gastroenterol 2006; 12: 853-857.
4. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001; 48: 132-135.
5. Grangette C, Nutten S, Palumbo E, et al. Enhanced anti-inflammatory capacity of a Lactobacillus planetarium mutant synthesizing modified teichoic acids. Proc Nat Acad Sci USA 2005; 102: 10321-10326.
6. Gionchetti P, Rizzello F, Lammers KM, et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 2006; 12: 3306-3313.
7. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 2004; 126: 1620-1633.
8. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005; 21: 426-430.
9. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698.
10. Furrie E, Macfarine S, Keenedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation In patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242-249.
11. Kato K, Mizuno S, Umesaki Y, et al. Randomised placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141.
12. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10: PI126-131.
13. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858.
14. Kruis W. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Dig Dis Week 2001, abstract 680.
15. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623.
16. Rembacken BJ, Snelling AM, Hawkey PM, Dixon ATR. A double blind trial on non pathogenic E. coli vs mesalazine for the treatment of ulcerative colitis. Gut 1997; 41: 3911.
17. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354: 635-639.
18. Bibiloni R, Fedorak RN, Tannack GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546.
19. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial on the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
20. Venturi A, Gioncherti P, Rizzelo P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1103-1108.
21. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574.
22. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409.
23. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalasine. Gastroenterology 2000; 118: A781.
24. Schultz M, Timmer A, Herfath H, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5.
25. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double-blind, placebo-controlled GETAID trial. Gut 2006; 55: 842-847.
26. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-658.
27. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease; results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453-457.
28. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464.
29. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
30. Akerlund JE, Lofberg R. Pouchitis. Curr Opin Gastroenterol 2004; 20: 341-344.
31. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114.
32. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-515.
33. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96: 2691-2699.
34. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62.
35. Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006; 40: 260-263.